0001437749-26-014900 | 10-Q | XBRL Viewer

Goodwill [Table Text Block]

	*Hospice*			*Personal Care*		*Home Health*			*Total*
	(Amounts in Thousands)
Goodwill as of December 31, 2025	$	432,866		$	468,981	$	94,849		$	996,696
Additions for acquisitions		—			—		—			—
Adjustments to previously recorded goodwill		(14	)		47		(49	)		(16	)
Goodwill as of March 31, 2026	$	432,852		$	469,028	$	94,800		$	996,680

Intangible Asset, Finite-Lived [Table Text Block]

		*March 31, 2026*							*December 31, 2025*
		(Amounts in Thousands)							(Amounts in Thousands)
	*Estimated Useful*	*Gross*		*Accumulated*			*Net*		*Gross*		*Accumulated*			*Net*
	*Life (years)*	*carrying value*		*amortization*			*carrying value*		*carrying value*		*amortization*			*carrying value*
Customer and referral relationships	3 - 15	$	34,026	$	(33,562	)	$	464	$	34,201	$	(33,656	)	$	545
Trade names and trademarks	1 - 20		58,859		(27,186	)		31,673		59,366		(26,535	)		32,831
Non-competition agreement	3 - 5		6,728		(6,691	)		37		6,728		(6,663	)		65
State Licenses	6 - 10		26,529		(4,845	)		21,684		26,529		(4,190	)		22,339
State Licenses	Indefinite		46,630		—			46,630		46,630		—			46,630
Total intangible assets		$	172,772	$	(72,284	)	$	100,488	$	173,454	$	(71,044	)	$	102,410

Tabular disclosure of goodwill.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Note 11 - Segment Information (Details Textual)	3 Months Ended
Note 11 - Segment Information (Details Textual)	Mar. 31, 2026
Number of Operating Segments	3
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	Chief Executive Officer [Member]
Number of Reportable Segments	3
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The Company’s method for measuring profitability on each reportable segment basis is the same as those described in the summary of significant accounting policies and its CODMs frequently review the actual result to budget variance to allocate resources to the segment and assess its performance. Segment operating income consists of revenue generated by a segment, less the direct costs of service revenues and general and administrative expenses that are incurred directly by the segment. Unallocated general and administrative costs are those costs for functions performed in a centralized manner and therefore not attributable to a particular segment. These costs include accounting, finance, human resources, legal, information technology, corporate office support and facility costs and overall corporate management.

Note 1 - Nature of Operations, Consolidation, and Presentation of Financial Statements (Details Textual)	3 Months Ended
	Mar. 31, 2026
Number of Operating Segments	3
Number of Reportable Segments	3

Note 5 - Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2026

Intangible Asset and Goodwill [Text Block]

5. Goodwill and Intangible Assets

A summary of the goodwill by segment and related adjustments is provided below:

	*Hospice*			*Personal Care*		*Home Health*			*Total*
	(Amounts in Thousands)
Goodwill as of December 31, 2025	$	432,866		$	468,981	$	94,849		$	996,696
Additions for acquisitions		—			—		—			—
Adjustments to previously recorded goodwill		(14	)		47		(49	)		(16	)
Goodwill as of March 31, 2026	$	432,852		$	469,028	$	94,800		$	996,680

The Company’s identifiable intangible assets consist of customer and referral relationships, trade names and trademarks, non-competition agreements, and state licenses. Amortization is computed using straight-line and accelerated methods based upon the estimated useful lives of the respective assets, which range from one to twenty years. Customer and referral relationships are amortized systematically over the periods of expected economic benefit, which range from three to fifteen years.

The carrying amount and accumulated amortization of each identifiable intangible asset category consisted of the following:

		*March 31, 2026*							*December 31, 2025*
		(Amounts in Thousands)							(Amounts in Thousands)
	*Estimated Useful*	*Gross*		*Accumulated*			*Net*		*Gross*		*Accumulated*			*Net*
	*Life (years)*	*carrying value*		*amortization*			*carrying value*		*carrying value*		*amortization*			*carrying value*
Customer and referral relationships	3 - 15	$	34,026	$	(33,562	)	$	464	$	34,201	$	(33,656	)	$	545
Trade names and trademarks	1 - 20		58,859		(27,186	)		31,673		59,366		(26,535	)		32,831
Non-competition agreement	3 - 5		6,728		(6,691	)		37		6,728		(6,663	)		65
State Licenses	6 - 10		26,529		(4,845	)		21,684		26,529		(4,190	)		22,339
State Licenses	Indefinite		46,630		—			46,630		46,630		—			46,630
Total intangible assets		$	172,772	$	(72,284	)	$	100,488	$	173,454	$	(71,044	)	$	102,410

Amortization expense related to the intangible assets was $1.9 million and $2.0 million for the three months ended March 31, 2026 and 2025, respectively. The weighted average remaining useful lives of identifiable intangible assets as of March 31, 2026 was 8.92 years.

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2026	Apr. 28, 2026
Document Information [Line Items]
Entity Central Index Key	0001468328
Entity Registrant Name	Addus HomeCare Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2026
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2026
Document Transition Report	false
Entity File Number	001-34504
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5340172
Entity Address, Address Line One	6303 Cowboys Way, Suite 600
Entity Address, City or Town	Frisco
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75034
City Area Code	469
Local Phone Number	535-8200
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ADUS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,664,776

Note 5 - Goodwill and Intangible Assets - Schedule of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2026 USD ($)
Goodwill, Balance	$ 996,696
Additions for acquisitions	0
Adjustments to previously recorded goodwill	(16)
Goodwill, Balance	996,680
Hospice Segment [Member]
Goodwill, Balance	432,866
Additions for acquisitions	0
Adjustments to previously recorded goodwill	(14)
Goodwill, Balance	432,852
Personal Care Segment [Member]
Goodwill, Balance	468,981
Additions for acquisitions	0
Adjustments to previously recorded goodwill	47
Goodwill, Balance	469,028
Home Health Segment [Member]
Goodwill, Balance	94,849
Additions for acquisitions	0
Adjustments to previously recorded goodwill	(49)
Goodwill, Balance	$ 94,800

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Mar. 31, 2026	Dec. 31, 2025
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	40,000	40,000
Common stock, shares issued (in shares)	18,665	18,518
Common stock, shares outstanding (in shares)	18,665	18,518

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current assets
Cash	$ 103,065	$ 81,617
Accounts receivable, net of allowances for credit losses	144,823	151,695
Prepaid expenses and other current assets	24,988	36,179
Total current assets	272,876	269,491
Property and equipment, net of accumulated depreciation and amortization	24,657	24,998
Other assets
Goodwill	996,680	996,696
Intangibles, net of accumulated amortization	100,488	102,410
Operating lease assets, net	40,999	43,713
Total other assets	1,138,167	1,142,819
Total assets	1,435,700	1,437,308
Current liabilities
Accounts payable	14,040	16,832
Accrued payroll	63,926	65,941
Accrued expenses	30,348	28,191
Operating lease liabilities, current portion	13,139	13,144
Government stimulus advances	14,637	11,699
Accrued workers' compensation insurance	13,385	13,680
Total current liabilities	149,475	149,487
Long-term liabilities
Long-term debt, net of debt issuance costs	91,274	120,959
Long-term operating lease liabilities	34,331	37,259
Deferred income tax	44,205	44,065
Other long-term liabilities	255	235
Total long-term liabilities	170,065	202,518
Total liabilities	319,540	352,005
Stockholders' equity
Common stock—$.001 par value; 40,000 authorized and 18,665 and 18,518 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	19	18
Additional paid-in capital	618,732	612,945
Retained earnings	497,409	472,340
Total stockholders' equity	1,116,160	1,085,303
Total liabilities and stockholders' equity	$ 1,435,700	$ 1,437,308

Note 12 - Significant Payors

3 Months Ended

Mar. 31, 2026

Concentration Risk Disclosure [Text Block]

12. Significant Payors

The Company’s revenue by payor type was as follows:

*Personal Care Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
State, local and other governmental programs	$	139,641		49.7	%	$	132,904		51.5	%
Managed care organizations		133,669		47.6			117,007		45.3
Private pay		6,227		2.2			6,976		2.7
Commercial insurance		1,106		0.4			1,160		0.4
Other		451		0.1			239		0.1
Total personal care segment net service revenues	$	281,094		100.0	%	$	258,286		100.0	%

*Hospice Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Medicare	$	62,101		94.4	%	$	56,788		92.4	%
Commercial insurance		1,810		2.8			2,383		3.9
Managed care organizations		1,492		2.3			2,028		3.3
Other		382		0.5			238		0.4
Total hospice segment net service revenues	$	65,785		100.0	%	$	61,437		100.0	%

*Home Health Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Medicare	$	10,227		61.1	%	$	12,576		69.9	%
Managed care organizations		3,970		23.7			3,810		21.2
State, local and other governmental programs (excluding Medicare)		2,046		12.2			1,087		6.0
Other		489		3.0			512		2.9
Total home health segment net service revenues	$	16,732		100.0	%	$	17,985		100.0	%

The Company derives a significant amount of its revenue from its operations in Illinois, New Mexico, Ohio, Tennessee, and Texas. The percentages of segment revenue for each of these significant states and New York for the three months ended March 31, 2026 and 2025, respectively, were as follows:

*Personal Care Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Illinois	$	116,750		41.5	%	$	111,414		43.1	%
Texas		57,390		20.4			49,861		19.3
New Mexico		30,490		10.8			28,305		11.0
New York(1)		—		—			273		0.1
All other states		76,464		27.3			68,433		26.5
Total personal care segment net service revenues	$	281,094		100.0	%	$	258,286		100.0	%

(1)

As a result of changes and uncertainty in New York regarding the CDPAP, the Company determined that its New York personal care operations no longer fit its growth strategy and is divesting these operations. See Note 3 to the Notes to Unaudited Condensed Consolidated Financial Statements, Divestiture, for additional details regarding our divestiture.

*Hospice Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Ohio	$	26,466		40.2	%	$	23,187		37.7	%
Illinois		14,339		21.8			14,564		23.7
New Mexico		7,871		12.0			7,913		12.9
All other states		17,109		26.0			15,773		25.7
Total hospice segment net service revenues	$	65,785		100.0	%	$	61,437		100.0	%

*Home Health Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
New Mexico	$	8,539		51.0	%	$	8,555		47.6	%
Tennessee		6,884		41.1			7,498		41.7
Illinois		1,309		7.9			1,932		10.7
Total home health segment net service revenues	$	16,732		100.0	%	$	17,985		100.0	%

A substantial portion of the Company’s revenue and accounts receivable are derived from services performed for federal, state, and local governmental agencies. The personal care segment derives a significant amount of its net service revenues in Illinois, which represented 32.1% and 33.0% of our net service revenues for the three months ended March 31, 2026 and 2025, respectively. The Illinois Department on Aging, the largest payor program for the Company’s Illinois personal care operations, accounted for 17.8% and 18.5% of the Company’s net service revenues for the three months ended March 31, 2026 and 2025, respectively.

The related receivables due from the Illinois Department on Aging represented 23.1% and 25.2% of the Company’s net accounts receivable at March 31, 2026 and December 31, 2025, respectively.

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-3A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-2A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/275/tableOfContent

Note 12 - Significant Payors (Details Textual)	3 Months Ended		12 Months Ended
Note 12 - Significant Payors (Details Textual)	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Geographic Concentration Risk [Member] \| Revenue from Contract with Customer Benchmark [Member] \| ILLINOIS
Concentration Risk, Percentage	32.10%	33.00%
Customer Concentration Risk [Member] \| Revenue from Contract with Customer Benchmark [Member] \| Illinois Department on Aging [Member]
Concentration Risk, Percentage	17.80%	18.50%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Illinois Department on Aging [Member]
Concentration Risk, Percentage	23.10%		25.20%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details

Note 13 - Subsequent Events

3 Months Ended

Mar. 31, 2026

Subsequent Events [Text Block]

13. Subsequent Events

On May 1, 2026, the Company completed the acquisition of substantially all of the assets of an Indiana limited liability company doing business as HomeCourt Home Care for approximately $12.5 million (the “HomeCourt Acquisition”). The purchase was funded through the Company’s available cash. The HomeCourt Acquisition expanded the Company’s services within its personal care segment in Indiana. The initial accounting is not yet complete, and therefore the related business combination disclosures have not been presented as the Company is currently in the process of valuing the assets acquired and liabilities assumed in the transaction.

Note 12 - Significant Payors - Revenue from External Customers by Products and Services (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2026

Mar. 31, 2025

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member]

$ 363,611

$ 337,708

$ 281,094

$ 258,286

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | State, Local, and Other Governmental Programs [Member]

100.00%

$ 139,641

$ 132,904

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | Managed Care Organizations [Member]

49.70%

51.50%

$ 133,669

$ 117,007

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | Commercial Insurance [Member]

47.60%

45.30%

$ 1,106

$ 1,160

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | Private Pay [Member]

0.40%

$ 6,227

$ 6,976

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | Other [Member]

2.20%

2.70%

$ 451

$ 239

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member]

0.10%

$ 65,785

$ 61,437

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | Medicare [Member]

100.00%

$ 62,101

$ 56,788

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | Managed Care Organizations [Member]

94.40%

92.40%

$ 1,492

$ 2,028

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | Commercial Insurance [Member]

2.30%

3.30%

$ 1,810

$ 2,383

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | Other [Member]

2.80%

3.90%

$ 382

$ 238

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member]

0.50%

0.40%

$ 16,732

$ 17,985

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member] | Medicare [Member]

100.00%

$ 10,227

$ 12,576

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member] | Managed Care Organizations [Member]

61.10%

69.90%

$ 3,970

$ 3,810

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member] | State, Local, and Other Governmental Programs (Excluding Medicare) [Member]

23.70%

21.20%

$ 2,046

$ 1,087

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member] | Other [Member]

12.20%

6.00%

$ 489

$ 512

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member]

3.00%

2.90%

$ 281,094

$ 258,286

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | ILLINOIS

100.00%

$ 116,750

$ 111,414

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | NEW MEXICO

41.50%

43.10%

$ 30,490

$ 28,305

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | TEXAS

10.80%

11.00%

$ 57,390

$ 49,861

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | NEW YORK

20.40%

19.30%

^[1]

$ 0

$ 273

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Personal Care Segment [Member] | All Other States [Member]

^[1]

0.00%

0.10%

$ 76,464

$ 68,433

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member]

27.30%

26.50%

$ 65,785

$ 61,437

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | ILLINOIS

100.00%

$ 14,339

$ 14,564

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | OHIO

21.80%

23.70%

$ 26,466

$ 23,187

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | NEW MEXICO

40.20%

37.70%

$ 7,871

$ 7,913

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Hospice Segment [Member] | All Other States [Member]

12.00%

12.90%

$ 17,109

$ 15,773

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member]

26.00%

25.70%

$ 16,732

$ 17,985

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member] | ILLINOIS

100.00%

$ 1,309

$ 1,932

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member] | NEW MEXICO

7.90%

10.70%

$ 8,539

$ 8,555

Geographic Concentration Risk [Member] | Revenue from Contract with Customer, Segment Benchmark [Member] | Home Health Segment [Member] | TENNESSEE

51.00%

47.60%

$ 6,884

$ 7,498

41.10%

41.70%

[1]

As a result of changes and uncertainty in New York regarding the CDPAP, the Company determined that its New York personal care operations no longer fit its growth strategy and is divesting these operations. See Note 3 to the Notes to Unaudited Condensed Consolidated Financial Statements, Divestiture, for additional details regarding our divestiture.

Note 5 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Intangible Asset, Finite-Lived, Amortization Expense	$ 1.9	$ 2.0
Intangible Asset, Finite-Lived, Remaining Amortization Period (Year)	8 years 11 months 1 day
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year
Minimum [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Maximum [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	15 years

Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

Use of Estimates, Policy [Policy Text Block]

Note 9 - Income Taxes (Details Textual)	3 Months Ended
Note 9 - Income Taxes (Details Textual)	Mar. 31, 2026	Mar. 31, 2025
Effective Income Tax Rate Reconciliation, Percent	22.70%	21.40%
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent	3.10%	4.70%

Note 4 - Leases - Schedule Of Balance Sheet Information, Related To Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Operating lease assets, net	$ 40,999	$ 43,713
Short-term operating lease liabilities	13,139	13,144
Long-term operating lease liabilities	34,331	37,259
Total operating lease liabilities	$ 47,470	$ 50,403

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Net service revenues	$ 363,611	$ 337,708
Cost of service revenues	247,738	230,031
Gross profit	115,873	107,677
General and Administrative Expense	77,771	73,220
Depreciation and amortization	4,030	3,943
Total operating expenses	81,801	77,163
Operating income	34,072	30,514
Interest income	(510)	(502)
Interest expense	2,151	4,018
Total interest expense, net	1,641	3,516
Income before income taxes	32,431	26,998
Income tax expense	7,362	5,770
Net income	$ 25,069	$ 21,228
Net income per common share
Basic income per share (in dollars per share)	$ 1.38	$ 1.18
Diluted income per share (in dollars per share)	$ 1.36	$ 1.16
Weighted average number of common shares and potential common shares outstanding:
Basic (in shares)	18,194	17,976
Diluted (in shares)	18,486	18,311

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2026

Accounting Policies [Abstract]

Estimates

The financial statements are prepared by management in conformity with GAAP and include estimated amounts and certain disclosures based on assumptions about future events. The Company’s critical accounting estimates include the following areas: revenue recognition, goodwill and intangibles and business combinations, and when required, the quantitative assessment of goodwill. Actual results could differ from those estimates.

Earnings Per Share, Policy [Policy Text Block]

Computation of Weighted Average Shares

The following table sets forth the computation of basic and diluted common shares:

	*For the Three Months Ended March 31,*
	(Amounts in thousands)
	*2026*		*2025*
Weighted average number of shares outstanding for basic per share calculation		18,194		17,976
Effect of dilutive potential shares:
Stock options		149		223
Restricted stock awards		143		112
Adjusted weighted average shares for diluted per share calculation		18,486		18,311
Anti-dilutive shares:
Stock options		—		—
Restricted stock awards		122		—

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Improvement to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-09 during the year ended December 31, 2025. Adoption of the standard did not have a material impact on the Company’s consolidated financial statements and expanded income tax disclosures.

In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets, which replaces the incurred-loss model with a forward-looking current expected credit loss model that requires recognition of lifetime expected credit losses on financial assets measured at amortized cost and certain off-balance-sheet credit exposures (including trade accounts receivable and contract assets), using historical experience, current conditions, and reasonable and supportable forecasts. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted. The disclosure updates should be applied prospectively. The Company adopted ASU 2025-05 during the three months ended March 31, 2026. Adoption did not have a material impact on the Company’s consolidated financial statements.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which intends to provide investors more detailed disclosures around specific types of expenses. The new disclosures require certain details for expenses presented on the face of the Consolidated Statements of Operations as well as selling expenses to be presented in the notes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The disclosure updates are required to be applied prospectively with the option for retrospective application. The Company is currently assessing the impact and timing of adopting the updated provisions.

In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The new guidance intends to modernize the guidance related to internal-use software costs to reflect current software development methods. It requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable the project will be completed and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, and may be adopted using a prospective, retrospective, or modified transition approach. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements.

In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which provides guidance on the recognition, measurement, and presentation of government grants. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, and interim periods within those fiscal years, and permits modified prospective, modified retrospective, or full retrospective adoption, with early adoption permitted. The Company has evaluated the guidance and does not expect adoption to have a material impact on its consolidated financial statements or related disclosures.

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies certain interim reporting guidance. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. The Company has evaluated the guidance and does not expect adoption to have a material impact on its consolidated financial statements.

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Note 4 - Leases - Schedule of Operating Lease Liability Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
2027	$ 15,636
2028	11,968
2029	8,337
2030	6,152
2031	5,284
Thereafter	8,502
Total future minimum rental commitments	55,879
Less: Imputed interest	(8,409)
Total lease liabilities	$ 47,470	$ 50,403

Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Weighted Average Number of Shares [Table Text Block]

	*For the Three Months Ended March 31,*
	(Amounts in thousands)
	*2026*		*2025*
Weighted average number of shares outstanding for basic per share calculation		18,194		17,976
Effect of dilutive potential shares:
Stock options		149		223
Restricted stock awards		143		112
Adjusted weighted average shares for diluted per share calculation		18,486		18,311
Anti-dilutive shares:
Stock options		—		—
Restricted stock awards		122		—

Note 9 - Income Taxes

3 Months Ended

Mar. 31, 2026

Income Tax Disclosure [Text Block]

9. Income Taxes

The effective income tax rates were 22.7% and 21.4% for the three months ended March 31, 2026 and 2025, respectively.

For the three months ended March 31, 2026, the difference between our federal statutory and effective income tax rates was principally due to the inclusion of state taxes, non-deductible compensation, partially offset by the use of federal employment tax credits and an excess tax benefit. For both the three months ended March 31, 2026 and 2025, the effective tax rates were inclusive of an excess tax benefit of 3.1% and 4.7%, respectively. The excess tax expense and tax benefit are discrete items, related to the vesting of equity shares, which requires the Company to recognize the expense or benefit fully in the period. An excess tax expense results if the Company’s cumulative costs of the award recognized exceed the income tax deduction, whereas an excess tax benefit results if the Company’s cumulative costs of the award recognized are less than the income tax deduction.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Note 4 - Leases (Tables)

3 Months Ended

Mar. 31, 2026

Schedule Of Balance Sheet Information, Related To Operating Leases [Table Text Block]

	*March 31, 2026*		*December 31, 2025*
	(Amounts in Thousands)
Operating lease assets, net	$	40,999	$	43,713

Short-term operating lease liabilities		13,139		13,144
Long-term operating lease liabilities		34,331		37,259
Total operating lease liabilities	$	47,470	$	50,403

Lease, Cost [Table Text Block]

	*For the Three Months Ended March 31,*
	(Amounts in Thousands)
	*2026*		*2025*
Operating lease costs	$	3,657	$	3,657
Short-term lease costs		254		284
Total lease costs		3,911		3,941
Less: sublease income		—		(226	)
Total lease costs, net	$	3,911	$	3,715

Schedule of Lease Term and Discount Rate [Table Text Block]

	*March 31, 2026*			*December 31, 2025*
Operating leases:
Weighted average remaining lease term		4.87			5.05
Weighted average discount rate		6.45	%		6.37	%

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

	*Operating Leases*
	(Amounts in Thousands)
Due in the 12-month period ended March 31,
2027	$	15,636
2028		11,968
2029		8,337
2030		6,152
2031		5,284
Thereafter		8,502
Total future minimum rental commitments		55,879
Less: Imputed interest		(8,409	)
Total lease liabilities	$	47,470

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

	*For the Three Months Ended March 31,*
	(Amounts in Thousands)
	*2026*		*2025*
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	4,179	$	4,182

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	2,295	$	979

Note 6 - Details of Certain Balance Sheet Accounts (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Other Current Assets [Table Text Block]

	*March 31, 2026*		*December 31, 2025*
	(Amounts in Thousands)
Income tax receivable	$	3,301	$	10,520
Prepaid payroll		5,676		7,960
Prepaid workers' compensation and liability insurance		3,220		5,694
Prepaid licensing fees		5,711		4,167
Workers' compensation insurance receivable		441		474
Other ⁽¹⁾		6,639		7,364
Total prepaid expenses and other current assets	$	24,988	$	36,179

Schedule of Accrued Liabilities [Table Text Block]

	*March 31, 2026*		*December 31, 2025*
	(Amounts in Thousands)
Accrued health benefits	$	7,449	$	6,643
Accrued professional fees		6,553		6,390
Accrued payroll and other taxes		4,367		2,242
Other		11,979		12,916
Total accrued expenses	$	30,348	$	28,191

Note 6 - Details of Certain Balance Sheet Accounts - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Accrued health benefits	$ 7,449	$ 6,643
Accrued professional fees	6,553	6,390
Accrued payroll and other taxes	4,367	2,242
Other	11,979	12,916
Total accrued expenses	$ 30,348	$ 28,191

Note 5 - Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Finite-Lived Intangible Assets, Accumulated Amortization	$ (72,284)	$ (71,044)
Total intangible assets	172,772	173,454
Total intangible assets	100,488	102,410
State Licenses [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Gross	$ 46,630	46,630
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Customer Relationships [Member]
Finite-Lived Intangible Assets, Gross	$ 34,026	34,201
Finite-Lived Intangible Assets, Accumulated Amortization	(33,562)	(33,656)
Finite-Lived Intangible Assets, Net	$ 464	545
Customer Relationships [Member] \| Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	3 years
Customer Relationships [Member] \| Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets, Gross	$ 58,859	59,366
Finite-Lived Intangible Assets, Accumulated Amortization	(27,186)	(26,535)
Finite-Lived Intangible Assets, Net	$ 31,673	32,831
Trademarks and Trade Names [Member] \| Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year
Trademarks and Trade Names [Member] \| Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Gross	$ 6,728	6,728
Finite-Lived Intangible Assets, Accumulated Amortization	(6,691)	(6,663)
Finite-Lived Intangible Assets, Net	$ 37	65
Noncompete Agreements [Member] \| Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	3 years
Noncompete Agreements [Member] \| Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
State Licenses [Member]
Finite-Lived Intangible Assets, Gross	$ 26,529	26,529
Finite-Lived Intangible Assets, Accumulated Amortization	(4,845)	(4,190)
Finite-Lived Intangible Assets, Net	$ 21,684	$ 22,339
State Licenses [Member] \| Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	6 years
State Licenses [Member] \| Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	10 years

Note 6 - Details of Certain Balance Sheet Accounts (Details Textual) - USD ($) $ in Millions	Mar. 31, 2026	Dec. 31, 2025
New York Asset Sale [Member]
Disposal Group, Including Discontinued Operation, Consideration Receivable Debt	$ 2.3	$ 2.3

Note 11 - Segment Information

3 Months Ended

Mar. 31, 2026

Segment Reporting [Text Block]

11. Segment Information

Operating segments are defined as components of a company that engage in business activities from which it may earn revenues and incur expenses, and for which separate financial information is available and is regularly reviewed by the Company’s CODM. The Company identifies its Chief Executive Officer and Chief Operating Officer together as CODMs to assess the performance of the individual segments and make decisions about resources to be allocated to the segments. The Company operates as a multi-state provider of three business segments providing in-home services.

In its personal care segment, the Company provides non-medical assistance with activities of daily living, primarily to persons who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. In its hospice segment, the Company provides physical, emotional, and spiritual care for people who are terminally ill as well as related services for their families. In its home health segment, the Company provides services that are primarily medical in nature to individuals who may require assistance during an illness or after hospitalization and include skilled nursing and physical, occupational, and speech therapy.

The Company’s method for measuring profitability on each reportable segment basis is the same as those described in the summary of significant accounting policies and its CODMs frequently review the actual result to budget variance to allocate resources to the segment and assess its performance. Segment operating income consists of revenue generated by a segment, less the direct costs of service revenues and general and administrative expenses that are incurred directly by the segment. Unallocated general and administrative costs are those costs for functions performed in a centralized manner and therefore not attributable to a particular segment. These costs include accounting, finance, human resources, legal, information technology, corporate office support and facility costs and overall corporate management.

The CODMs do not review disaggregated assets by segment. The measure of segment assets is reported on the balance sheet as total consolidated assets.

The tables below set forth information about the Company’s reportable segments, along with the items necessary to reconcile the segment information to the totals reported in the accompanying Unaudited Condensed Consolidated Financial Statements.

	*For the Three Months Ended March 31, 2026*
	(Amounts in Thousands)
	*Personal Care*		*Hospice*		*Home Health*		*Total*
Net service revenues	$	281,094	$	65,785	$	16,732	$	363,611
Direct service personnel		202,872		29,168		8,834		240,874
General and administrative salaries, wages and benefits		19,298		12,162		3,598		35,058
Other segment items ¹		6,058		9,803		1,137		16,998
Segment operating income		52,866		14,652		3,163		70,681
Segment reconciliation:
Items not allocated at segment level:
Other general and administrative expenses								32,579
Depreciation and amortization								4,030
Interest income								(510	)
Interest expense								2,151
Income before income taxes							$	32,431

(1)

Other segment items include other costs for direct service personnel, office expense, licenses and taxes, communication, medical director fees, travel, and bad debt expense.

	*For the Three Months Ended March 31, 2025*
	(Amounts in Thousands)
	*Personal Care*		*Hospice*		*Home Health*		*Total*
Net service revenues	$	258,286	$	61,437	$	17,985	$	337,708
Direct service personnel		186,650		26,205		10,413		223,268
General and administrative salaries, wages and benefits		18,239		10,980		3,279		32,498
Other segment items ¹		5,805		9,635		1,279		16,719
Segment operating income		47,592		14,617		3,014		65,223
Segment reconciliation:
Items not allocated at segment level:
Other general and administrative expenses								30,766
Depreciation and amortization								3,943
Interest income								(502	)
Interest expense								4,018
Income before income taxes							$	26,998

(1)

Other segment items include other costs for direct service personnel, office expense, licenses and taxes, communication, medical director fees, travel, and bad debt expense.

The entire disclosure for segment reporting.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Note 7 - ARPA Spending Plans

3 Months Ended

Mar. 31, 2026

Government Assistance [Text Block]

7. ARPA Spending Plans

To mitigate the fiscal effects of the COVID-19 public health emergency, the American Rescue Plan Act of 2021 (“ARPA”) provided for a 10-percentage point increase in federal matching funds for Medicaid home and community-based services (“HCBS”) from April 1, 2021, through March 31, 2022, provided the states satisfied certain conditions. States must submit periodic HCBS spending plans to CMS regarding the federal and state funds tied to the increase in federal matching funds. Although states were generally permitted to use the associated state funds by March 31, 2025, CMS granted extensions to several states and some state spending plans continue through September 30, 2026.

HCBS spending plans for the additional matching funds vary by state, but common initiatives in which the Company participates include those aimed at strengthening the provider workforce (e.g., efforts to recruit, retain, and train direct service providers). The Company is required to properly and fully document the use of such funds in reports to the state in which the funds originated. Funds may be subject to recoupment if not expended or if they are expended on non-approved uses.

During the three months ended March 31, 2026, the Company received additional state funding provided by the ARPA of $6.2 million. Of the total state funding received by the Company pursuant to the ARPA through March 31, 2026, the Company utilized $3.2 million during the three months ended March 31, 2026, primarily for caregivers and adding support to recruiting and retention efforts, included as a reduction of cost of service revenues in the Company’s Unaudited Condensed Consolidated Statements of Income. As of March 31, 2026, the deferred portion of ARPA funding of $14.6 million is included within Government stimulus advances on the Company’s Unaudited Condensed Consolidated Balance Sheets.

Note 4 - Leases - Schedule of Cash Flow, Supplemental Disclosures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating cash flows from operating leases	$ 4,179	$ 4,182
Operating leases	$ 2,295	$ 979

Note 1 - Nature of Operations, Consolidation, and Presentation of Financial Statements

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Nature of Operations, Consolidation, and Presentation of Financial Statements

Addus HomeCare Corporation (“Holdings”) and its subsidiaries (together with Holdings, the “Company”, “we”, “us”, or “our”) operate as a multi-state provider of three distinct but related business segments providing in-home services. In its personal care segment, the Company provides non-medical assistance with activities of daily living, primarily to persons who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill, or disabled. In its hospice segment, the Company provides physical, emotional, and spiritual care for people who are terminally ill as well as related services for their families. In its home health segment, the Company provides services that are primarily medical in nature to individuals who may require assistance during an illness or after hospitalization and include skilled nursing and physical, occupational, and speech therapy. The Company’s payors include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals.

Basis of Presentation

The accompanying Unaudited Condensed Consolidated Financial Statements and related notes have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for Quarterly Reports on Form 10-Q. The accompanying balance sheet as of December 31, 2025 has been derived from the Company’s audited financial statements for the year ended December 31, 2025 previously filed with the SEC. Accordingly, these financial statements do not include all of the information and note disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for annual financial statements and should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2025 included in our Annual Report on Form 10-K, as amended (“Annual Report on Form 10-K”), which includes information and disclosures not included herein.

In the opinion of management, these financial statements reflect all adjustments of a normal, recurring nature necessary for the fair statement of our financial position, results of operations, and cash flows for the interim periods presented in conformity with GAAP. Our results for any interim period are not necessarily indicative of results for a full year or any other interim period.

Principles of Consolidation

These Unaudited Condensed Consolidated Financial Statements include the accounts of Addus HomeCare Corporation and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Note 12 - Significant Payors (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table Text Block]

*Personal Care Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
State, local and other governmental programs	$	139,641		49.7	%	$	132,904		51.5	%
Managed care organizations		133,669		47.6			117,007		45.3
Private pay		6,227		2.2			6,976		2.7
Commercial insurance		1,106		0.4			1,160		0.4
Other		451		0.1			239		0.1
Total personal care segment net service revenues	$	281,094		100.0	%	$	258,286		100.0	%

*Hospice Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Medicare	$	62,101		94.4	%	$	56,788		92.4	%
Commercial insurance		1,810		2.8			2,383		3.9
Managed care organizations		1,492		2.3			2,028		3.3
Other		382		0.5			238		0.4
Total hospice segment net service revenues	$	65,785		100.0	%	$	61,437		100.0	%

*Home Health Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Medicare	$	10,227		61.1	%	$	12,576		69.9	%
Managed care organizations		3,970		23.7			3,810		21.2
State, local and other governmental programs (excluding Medicare)		2,046		12.2			1,087		6.0
Other		489		3.0			512		2.9
Total home health segment net service revenues	$	16,732		100.0	%	$	17,985		100.0	%

*Personal Care Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Illinois	$	116,750		41.5	%	$	111,414		43.1	%
Texas		57,390		20.4			49,861		19.3
New Mexico		30,490		10.8			28,305		11.0
New York(1)		—		—			273		0.1
All other states		76,464		27.3			68,433		26.5
Total personal care segment net service revenues	$	281,094		100.0	%	$	258,286		100.0	%

*Hospice Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
Ohio	$	26,466		40.2	%	$	23,187		37.7	%
Illinois		14,339		21.8			14,564		23.7
New Mexico		7,871		12.0			7,913		12.9
All other states		17,109		26.0			15,773		25.7
Total hospice segment net service revenues	$	65,785		100.0	%	$	61,437		100.0	%

*Home Health Segment*	*For the Three Months Ended March 31,*
	*2026*					*2025*
			*% of Segment*					*% of Segment*
	*Amount*		*Net Service*			*Amount*		*Net Service*
	*(in Thousands)*		*Revenues*			*(in Thousands)*		*Revenues*
New Mexico	$	8,539		51.0	%	$	8,555		47.6	%
Tennessee		6,884		41.1			7,498		41.7
Illinois		1,309		7.9			1,932		10.7
Total home health segment net service revenues	$	16,732		100.0	%	$	17,985		100.0	%

Note 6 - Details of Certain Balance Sheet Accounts - Schedule of Other Current Assets (Details) - USD ($)
$ in Thousands

Mar. 31, 2026

Dec. 31, 2025

Income tax receivable

$ 3,301

$ 10,520

Prepaid payroll

5,676

7,960

Prepaid workers' compensation and liability insurance

3,220

5,694

Prepaid licensing fees

5,711

4,167

Workers' compensation insurance receivable

441

474

Other (1)

^[1]

6,639

7,364

Total prepaid expenses and other current assets

$ 24,988

$ 36,179

[1]	Included $2.3 million related to the New York Asset Sale deferred payments as of March 31, 2026 and December 31, 2025, respectively.

Note 11 - Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2026

Mar. 31, 2025

$ 363,611

$ 337,708

Depreciation and amortization

34,072

30,514

4,030

3,943

Interest income

(510)

(502)

Interest expense

2,151

4,018

Operating Segments [Member]

363,611

337,708

General and administrative salaries, wages and benefits

240,874

223,268

35,058

32,498

^[1]

16,998

16,719

Other general and administrative expenses

70,681

65,223

32,579

30,766

Depreciation and amortization

4,030

3,943

Interest income

(510)

(502)

Interest expense

2,151

4,018

Income before income taxes

32,431

26,998

Operating Segments [Member] | Personal Care [Member]

281,094

258,286

General and administrative salaries, wages and benefits

202,872

186,650

19,298

18,239

^[1]

6,058

5,805

Operating Segments [Member] | Hospice [Member]

52,866

47,592

65,785

61,437

General and administrative salaries, wages and benefits

29,168

26,205

12,162

10,980

^[1]

9,803

9,635

Operating Segments [Member] | Home Health [Member]

14,652

14,617

16,732

17,985

General and administrative salaries, wages and benefits

8,834

10,413

3,598

3,279

^[1]

1,137

1,279

$ 3,163

$ 3,014

[1]	Other segment items include other costs for direct service personnel, office expense, licenses & taxes, communication, medical director fees, travel and bad debt expense.

Note 13 - Subsequent Events (Details Textual) $ in Millions	Apr. 01, 2026 USD ($)
Subsequent Event [Member] \| HomeCourt Acquisition [Member]
Payments to Acquire Businesses, Gross	$ 12.5

Note 3 - Divesture

3 Months Ended

Mar. 31, 2026

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

3. Divestiture

Effective May 20, 2024, the Company entered into a definitive asset purchase agreement to sell all of the Company’s New York operations for a purchase price of up to $23.0 million in cash, subject to certain adjustments, including adjustments for future operating requirements (the “New York Asset Sale”). The purchase price included 50% cash consideration, paid out as an initial payment of $4.6 million and $6.9 million paid pro rata as a deferred payment as caregivers are transferred, and 50% in the form of contingent consideration for the Company’s New York Consumer Directed Personal Assistance Program (“CDPAP”) business. No amount was recorded related to the CDPAP business contingent consideration. The Company entered into a consulting agreement with the purchaser effective May 20, 2024, as the transfer of clients and caregivers and payment for assets pursuant to the New York Asset Sale is occurring over time as regulatory approvals are received, coordination of the transfer of clients and caregivers occurs, and the change of control takes place. The Company determined that the consulting agreement gave it the ability to control the business until October 2024, when the Company determined that it no longer controlled the business as it transferred more than 50% of the clients and caregivers and therefore qualified for sale consideration of the New York Asset Sale. As a result, the Company deconsolidated the results of its New York operations and recorded a gain on divestiture of $3.7 million during the year ended December 31, 2024. The gain was reflected within general and administrative expenses on the consolidated statement of operations. During the three months ended March 31, 2026, the Company recorded a lease modification reducing operating lease assets and liabilities by $1.6 million.

Note 4 - Leases

3 Months Ended

Mar. 31, 2026

Lessee, Operating Leases [Text Block]

4. Leases

Amounts reported on the Company’s Unaudited Condensed Consolidated Balance Sheets for operating leases were as follows:

	*March 31, 2026*		*December 31, 2025*
	(Amounts in Thousands)
Operating lease assets, net	$	40,999	$	43,713

Short-term operating lease liabilities		13,139		13,144
Long-term operating lease liabilities		34,331		37,259
Total operating lease liabilities	$	47,470	$	50,403

Lease Costs

Components of lease costs were reported in general and administrative expenses in the Company’s Unaudited Condensed Consolidated Statements of Income as follows:

	*For the Three Months Ended March 31,*
	(Amounts in Thousands)
	*2026*		*2025*
Operating lease costs	$	3,657	$	3,657
Short-term lease costs		254		284
Total lease costs		3,911		3,941
Less: sublease income		—		(226	)
Total lease costs, net	$	3,911	$	3,715

Lease Term and Discount Rate

Weighted average remaining lease terms and discount rates were as follows:

	*March 31, 2026*			*December 31, 2025*
Operating leases:
Weighted average remaining lease term		4.87			5.05
Weighted average discount rate		6.45	%		6.37	%

Maturity of Lease Liabilities

Remaining operating lease payments as of March 31, 2026 were as follows:

	*Operating Leases*
	(Amounts in Thousands)
Due in the 12-month period ended March 31,
2027	$	15,636
2028		11,968
2029		8,337
2030		6,152
2031		5,284
Thereafter		8,502
Total future minimum rental commitments		55,879
Less: Imputed interest		(8,409	)
Total lease liabilities	$	47,470

Supplemental Cash Flows Information

	*For the Three Months Ended March 31,*
	(Amounts in Thousands)
	*2026*		*2025*
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	4,179	$	4,182

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	2,295	$	979

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2026

Significant Accounting Policies [Text Block]

2. Summary of Significant Accounting Policies

Estimates

Computation of Weighted Average Shares

The following table sets forth the computation of basic and diluted common shares:

	*For the Three Months Ended March 31,*
	(Amounts in thousands)
	*2026*		*2025*
Weighted average number of shares outstanding for basic per share calculation		18,194		17,976
Effect of dilutive potential shares:
Stock options		149		223
Restricted stock awards		143		112
Adjusted weighted average shares for diluted per share calculation		18,486		18,311
Anti-dilutive shares:
Stock options		—		—
Restricted stock awards		122		—

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Note 3 - Divesture (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		12 Months Ended
	May 20, 2024	Oct. 31, 2024	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2024
Proceeds from Divestiture of Businesses			$ 0	$ 3,848
Increase (Decrease) in Operating Lease Right-of-use Asset			(1,600)
New York Asset Sale [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 23,000
Disposal Group, Including Discontinued Operation, Cash Consideration, Percent	50.00%
Proceeds from Divestiture of Businesses	$ 4,600
Disposal Group, Including Discontinued Operation, Consideration Receivable Debt	$ 6,900
Disposal Group, Including Discontinued Operation, Contingent Consideration, Percent	50.00%
Divesture of Businesses, Consideration Transferred, Percentage		50.00%
Gain (Loss) on Disposition of Business					$ 3,700
Increase (Decrease) in Operating Lease Liability			$ (1,600)

Note 2 - Summary of Significant Accounting Policies - Schedule of Weighted Average Number of Shares (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Basic (in shares)	18,194	17,976
Diluted (in shares)	18,486	18,311
Share-Based Payment Arrangement, Option [Member]
Stock options (in shares)	149	223
Stock options, Anti-dilutive (in shares)	0	0
Restricted Stock [Member]
Stock options (in shares)	143	112
Stock options, Anti-dilutive (in shares)	122	0

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2024	18,148
Balance at Dec. 31, 2024	$ 18	$ 594,044	$ 376,430	$ 970,492
Issuance of shares of common stock under restricted stock award agreements (in shares)	227
Issuance of shares of common stock under restricted stock award agreements	$ 0	0	0	0
Forfeiture of shares of common stock under restricted stock award agreements (in shares)	(1)
Forfeiture of shares of common stock under restricted stock award agreements	$ 0	0	0	0
Stock-based compensation	$ 0	3,170	0	3,170
Shares issued for exercise of stock options (in shares)	25
Shares issued for exercise of stock options	$ 0	493	0	493
Net income	$ 0	0	21,228	21,228
Balance (in shares) at Mar. 31, 2025	18,399
Balance at Mar. 31, 2025	$ 18	597,707	397,658	995,383
Balance (in shares) at Dec. 31, 2025	18,518
Balance at Dec. 31, 2025	$ 18	612,945	472,340	1,085,303
Issuance of shares of common stock under restricted stock award agreements (in shares)	126
Issuance of shares of common stock under restricted stock award agreements	$ 1	0	0	1
Forfeiture of shares of common stock under restricted stock award agreements (in shares)	(1)
Forfeiture of shares of common stock under restricted stock award agreements	$ 0	0	0	0
Stock-based compensation	$ 0	5,000	0	5,000
Shares issued for exercise of stock options (in shares)	21
Shares issued for exercise of stock options	$ 0	787	0	787
Net income	$ 0	0	25,069	25,069
Balance (in shares) at Mar. 31, 2026	18,664
Balance at Mar. 31, 2026	$ 19	$ 618,732	$ 497,409	$ 1,116,160

Note 8 - Long-Term Debt - Schedule of Debt Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Less unamortized issuance costs	$ (3,061)	$ (3,376)
Long-term debt	91,274	120,959
Capital One, National Association [Member] \| Revolving Credit Facility [Member]
Revolving loan under the credit facility	$ 94,335	$ 124,335

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-4

Note 8 - Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Long-Term Debt Instruments [Table Text Block]

	*March 31, 2026*			*December 31, 2025*
	(Amounts in Thousands)
Revolving loan under the credit facility	$	94,335		$	124,335
Less unamortized issuance costs		(3,061	)		(3,376	)
Long-term debt	$	91,274		$	120,959

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Note 11 - Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Table Text Block]

	*For the Three Months Ended March 31, 2026*
	(Amounts in Thousands)
	*Personal Care*		*Hospice*		*Home Health*		*Total*
Net service revenues	$	281,094	$	65,785	$	16,732	$	363,611
Direct service personnel		202,872		29,168		8,834		240,874
General and administrative salaries, wages and benefits		19,298		12,162		3,598		35,058
Other segment items ¹		6,058		9,803		1,137		16,998
Segment operating income		52,866		14,652		3,163		70,681
Segment reconciliation:
Items not allocated at segment level:
Other general and administrative expenses								32,579
Depreciation and amortization								4,030
Interest income								(510	)
Interest expense								2,151
Income before income taxes							$	32,431

	*For the Three Months Ended March 31, 2025*
	(Amounts in Thousands)
	*Personal Care*		*Hospice*		*Home Health*		*Total*
Net service revenues	$	258,286	$	61,437	$	17,985	$	337,708
Direct service personnel		186,650		26,205		10,413		223,268
General and administrative salaries, wages and benefits		18,239		10,980		3,279		32,498
Other segment items ¹		5,805		9,635		1,279		16,719
Segment operating income		47,592		14,617		3,014		65,223
Segment reconciliation:
Items not allocated at segment level:
Other general and administrative expenses								30,766
Depreciation and amortization								3,943
Interest income								(502	)
Interest expense								4,018
Income before income taxes							$	26,998

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Note 7 - ARPA Spending Plans (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Government Assistance, Liability, Increase, Current	$ 6,200
Government Assistance, Operating Expense, Decrease (Increase)	3,200
Government Assistance, Liability, Current	$ 14,637	$ 11,699
Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]	General and Administrative Expense

Insider Trading Arrangements

3 Months Ended

Mar. 31, 2026

Material Terms of Trading Arrangement [Text Block]

Item 5. Other Information

During the quarter ended March 31, 2026, each of the following directors and Section 16 officers adopted a Rule 10b5-1 Trading Arrangement (as defined in Item 408(a) of Regulation S-K) to sell common shares:

				Shares Vesting and Subject to	Other Shares Being Sold
Name	Title	Adoption Date	Expiration Date (1)	Sell-To-Cover (2)	(Subject to Certain Conditions)
Roberton Stevenson	EVP and Chief Human Resources Officer	March 5, 2026	February 23, 2027	3,521	n/a
Michael Wattenbarger	EVP and Chief Information Officer	March 3, 2026	February 23, 2027	3,852	n/a
R. Dirk Allison	Chief Executive Officer and Chairman of the Board	March 2, 2026	February 23, 2027	32,492	n/a
Darby Anderson	EVP and Chief Government Affairs & Community Relations Officer	March 3, 2026	February 23, 2027	4,901	n/a
Heather Brianne Dixon	President and Chief Operating Officer	March 6, 2026	September 15, 2027	13,614	n/a
Cliff Blessing	EVP and Chief Development Officer	March 6, 2026	February 23, 2027	3,521	n/a
Brian Poff	EVP, Chief Financial Officer, Secretary and Treasurer	March 2, 2026	February 23, 2027	13,101	n/a
Monica Raines	EVP and Chief Compliance and Quality Officer	March 5, 2026	February 23, 2027	3,521	n/a
Sean Gaffney	EVP and Chief Legal Officer	March 5, 2026	February 23, 2027	4,901	n/a
David Tucker	EVP and Chief Strategy Officer	March 5, 2026	February 23, 2027	4,277	n/a

(1) Each plan will expire on the date represented in the table or upon the earlier completion of all transactions contemplated by the arrangement.

(2) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.

Each trading arrangement noted above is intended to satisfy the affirmative defense in Rule 10b5-1(c). No other director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements, as such terms are defined in Item 408(a) of Regulation S-K, during the quarter ending March 31, 2026.

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Rule 10b5-1 Arrangement Terminated [Flag]

false

Roberton Stevenson [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

3,521

Roberton Stevenson

EVP and Chief Human Resources Officer

March 5, 2026

Michael Wattenbarger [Member]

February 23, 2027

Trading Arrangement, Securities Aggregate Available Amount

true

3,852

Michael Wattenbarger

EVP and Chief Information Officer

March 3, 2026

February 23, 2027

R. Dirk Allison [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

32,492

R. Dirk Allison

Chief Executive Officer and Chairman of the Board

March 2, 2026

February 23, 2027

Darby Anderson [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

4,901

Darby Anderson

EVP and Chief Government Affairs & Community Relations Officer

March 3, 2026

Heather Brianne Dixon [Member]

February 23, 2027

Trading Arrangement, Securities Aggregate Available Amount

true

13,614

Heather Brianne Dixon

President and Chief Operating Officer

March 6, 2026

September 15, 2027

Cliff Blessing [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

3,521

Cliff Blessing

EVP and Chief Development Officer

March 6, 2026

February 23, 2027

Brian Poff [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

13,101

Brian Poff

EVP, Chief Financial Officer, Secretary and Treasurer

March 2, 2026

February 23, 2027

Monica Raines [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

3,521

Monica Raines

EVP and Chief Compliance and Quality Officer

March 5, 2026

February 23, 2027

Sean Gaffney [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

4,901

Sean Gaffney

EVP and Chief Legal Officer

March 5, 2026

February 23, 2027

David Tucker [Member]

Trading Arrangement, Securities Aggregate Available Amount

true

4,277

David Tucker

EVP and Chief Strategy Officer

March 5, 2026

February 23, 2027

Note 8 - Long-Term Debt

3 Months Ended

Mar. 31, 2026

Long-Term Debt [Text Block]

8. Long-Term Debt

Long-term debt consisted of the following:

	*March 31, 2026*			*December 31, 2025*
	(Amounts in Thousands)
Revolving loan under the credit facility	$	94,335		$	124,335
Less unamortized issuance costs		(3,061	)		(3,376	)
Long-term debt	$	91,274		$	120,959

Amended and Restated Senior Secured Credit Facility

On October 31, 2018, the Company entered into the Amended and Restated Credit Agreement, with certain lenders and Capital One, National Association, as a lender and as agent for all lenders, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of September 12, 2019, as further amended by the Second Amendment to Amended and Restated Credit Agreement, dated as of July 30, 2021, as further amended by the Third Amendment to Amended and Restated Credit Agreement, dated as of April 26, 2023, and as further amended by the Fourth Amendment to Amended and Restated Credit Agreement, dated as of October 22, 2024 (as described below, the “Fourth Amendment”) (as amended, the “Credit Agreement”, as used throughout this Quarterly Report on Form 10-Q, “credit facility” shall mean the credit facility evidenced by the Credit Agreement). The credit facility consists of a $650.0 million revolving credit facility and a $150.0 million incremental loan facility, which incremental loan facility may be for term loans or an increase to the revolving loan commitments. The maturity of this credit facility is July 30, 2028.

On October 22, 2024, the Company entered into the Fourth Amendment to, among other things, (a) increase the Company’s revolving credit facility to an aggregate amount of $650.0 million, (b) increase the Company’s incremental loan facility to an aggregate amount of $150.0 million, and (c) extend the maturity date of the credit facility from July 30, 2026 to July 30, 2028.

Interest on the credit facility may be payable at (x) the sum of (i) an applicable margin ranging from 0.75% to 1.50% based on the applicable senior net leverage ratio plus (ii) a base rate equal to the greatest of (a) the rate of interest last quoted by The Wall Street Journal as the “prime rate,” (b) the sum of the federal funds rate plus a margin of 0.50%, and (c) the sum of Term Secured Overnight Financing Rate (“SOFR”) (as published by the CME Group Benchmark Administrative Limited) for an interest period of one month for such applicable day (not to be less than 0.00%), plus a margin of 1.00% or (y) the sum of (i) an applicable margin ranging from 1.75% to 2.50% based on the applicable senior net leverage ratio plus (ii) the rate per annum equal to the sum of Term SOFR (as published by the CME Group Benchmark Administrative Limited) for the applicable interest period (not to be less than 0.00%). Swing loans may not be SOFR loans.

Addus HealthCare, Inc. (“Addus HealthCare”) is the borrower, and its parent, Holdings, and substantially all of Holdings’ subsidiaries are guarantors under this credit facility, and it is collateralized by a first priority security interest in all of the Company’s and the other credit parties’ current and future tangible and intangible assets, including the shares of stock of the borrower and subsidiaries. The Credit Agreement contains affirmative and negative covenants customary for credit facilities of this type, including limitations on the Company with respect to liens, indebtedness, guaranties, investments, distributions, mergers and acquisitions, and dispositions of assets. The availability of additional draws under this credit facility is conditioned, among other things, upon (after giving effect to such draws) the Total Net Leverage Ratio (as defined in the Credit Agreement) not exceeding 3.75:1.00. In certain circumstances, in connection with a Material Acquisition (as defined in the Credit Agreement), the Company can elect to increase its Total Net Leverage Ratio compliance covenant to 4.25:1.00 for the then current fiscal quarter and the three succeeding fiscal quarters.

The Company pays a fee ranging from 0.20% to 0.35% based on the applicable senior net leverage ratio times the unused portion of the revolving loan portion of the credit facility.

The Credit Agreement contains customary affirmative covenants regarding, among other things, the maintenance of records, compliance with laws, maintenance of permits, maintenance of insurance and property and payment of taxes. The Credit Agreement also contains certain customary financial covenants and negative covenants that, among other things, include a requirement to maintain a minimum Interest Coverage Ratio (as defined in the Credit Agreement) and a requirement to stay below a maximum Total Net Leverage Ratio (as defined in the Credit Agreement). The Credit Agreement also contains restrictions on guarantees, indebtedness, liens, investments and loans, subject to customary carve outs, a restriction on dividends (provided that Addus HealthCare may make distributions to the Company in an amount that does not exceed $10.0 million in any year absent of an event of default, plus limited exceptions for tax and administrative distributions), a restriction on the ability to consummate acquisitions (without the consent of the lenders) under its credit facility subject to compliance with the Total Net Leverage Ratio (as defined in the Credit Agreement) thresholds, restrictions on mergers, dispositions of assets, and affiliate transactions, and restrictions on fundamental changes and lines of business.

During the three months ended March 31, 2026, the Company did not draw on its credit facility and repaid $30.0 million under the revolving credit facility.

As of March 31, 2026, the Company had a total of $94.3 million of revolving loans, with an interest rate of 5.43%, outstanding on its credit facility. After giving effect to the amount drawn on its credit facility, approximately $7.9 million of outstanding letters of credit and borrowing limits based on an advance multiple of adjusted EBITDA (as defined in the Credit Agreement), the Company had $650.0 million of capacity and $547.8 million available for borrowing under its credit facility. As of December 31, 2025, the Company had a total of $124.3 million of revolving loans, with an interest rate of 5.48%, outstanding on its credit facility.

As of March 31, 2026, the Company was in compliance with all financial covenants under the Credit Agreement.

Note 10 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2026

Commitments and Contingencies Disclosure [Text Block]

10. Commitments and Contingencies

Legal Proceedings

From time to time, the Company is subject to legal and/or administrative proceedings incidental to its business.

It is the opinion of management that the outcome of pending legal and/or administrative proceedings will not have a material effect on the Company’s Unaudited Condensed Consolidated Balance Sheets and Unaudited Condensed Consolidated Statements of Income.

Note 6 - Details of Certain Balance Sheet Accounts

3 Months Ended

Mar. 31, 2026